

#5
Gp 165 Jpp.
8/17/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Robert GARFIELD et al. : Group Art Unit: 1651
Serial No.: 09/121,849 *hgn* : Examiner: H. Lilling
Filed: July 24, 1998 :



For: TREATMENT OF PREECLAMPSIA, TOXEMIA AND PRETERM LABOR WITH
COMBINATION OF PROGESTATIONAL AGENT AND A NITRIC OXIDE
SYNTHASE SUBSTRATE AND/OR DONOR

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Restriction Requirement mailed July 8, 1999 (Paper No. 4), and further to the Preliminary Amendment submitted on July 24, 1998, Applicants hereby elect the species of a cyclooxygenase inhibitor which is aspirin.

REMARKS

If the Examiner requires any additional information or wishes to issue any additional Restriction Requirements, he is respectfully requested to contact the undersigned counsel at (703) 812-5317.

RECEIVED

Respectfully submitted,

AUG 10 1999

TECH CENTER 1600/2900

Richard M. Lebovitz (Reg. No. 37,067)
Attorney for Applicants
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
Direct Dial: (703) 812-5317

Filed: August 9, 1999

RML/njr

K:\PAT\Sch\1237 D1\response to restriction.wpd